Chongqing Genrix Biopharmaceutical Co., Ltd. Class ASSE: 688443

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of GR1803 Injection for the Treatment of Systemic Lupus Erythematosus

· Issued by Chongqing Genrix Biopharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of GR1803 Injection for the Treatment of Systemic Lupus Erythematosus

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis